SCHEMBL2184244

SCHEMBL2184244

CN(C)S(=O)(=O)n1cnc(-c2ccccc2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.54
FAAH O00519 1/20 0.43
LMNA P02545 1/20 0.40
TP53 P04637 1/20 0.40
MAPT P10636 1/20 0.40
THRB P10828 1/20 0.40
RECQL P46063 1/20 0.40
BLM P54132 1/20 0.40
ATM Q13315 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
NLRP3 Q96P20 1/20 0.40
KDM4E B2RXH2 3/20 0.39
GAA P10253 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HTT P42858 1/20 0.39
CYP2E1 P05181 1/20 0.37
CYP2A6 P11509 1/20 0.37
CYP2C9 P11712 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4046417 0.84 MEN1 (0.40) TSHRLMNATP53MAPTNPSR1
SCHEMBL7688500 0.84 TSHR (0.38) TSHRLMNATP53MAPTNPC1
SCHEMBL2719936 0.82 MAPT (0.46) LMNATP53MAPTNPSR1NPC1
SCHEMBL8523674 0.81 TSHR (0.43) TSHRFAAHLMNATP53MAPT
SCHEMBL7667658 0.80 ALDH1A1 (0.48) LMNAMAPTBLMNPSR1NPC1
SCHEMBL10715481 0.78 NPC1 (0.42) TSHRFAAHMAPTNPC1RAB9A
SCHEMBL19656045 0.77 BPTF (0.40) TSHRFAAHMAPTNPC1RAB9A
SCHEMBL9436796 0.75 MEN1 (0.38) TSHRTP53NPSR1NPC1RAB9A
SCHEMBL22075719 0.74 MEN1 (0.41) TSHRLMNATP53MAPTTHRB
SCHEMBL3637203 0.72 JAK2 (0.48)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3318561-B1 HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC (US) 2021-12-22 EP disclosed
US-10562916-B2 Substituted quinoxalines as PDE-10 inhibitors SUNOVION PHARMACEUTICALS, INC. (US) 2020-02-18 US disclosed
EP-2576540-B1 HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC (US) 2019-09-04 EP disclosed
EP-3318561-A1 HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF Sunovion Pharmaceuticals Inc. (US) 2018-05-09 EP disclosed
US-20180037590-A1 SUBSTITUTED QUINOLINES AS PDE-10 INHIBITORS SUNOVION PHARMACEUTICALS INC. 2018-02-08 US disclosed
US-9834564-B2 Substituted quinolines as PDE-10 inhibitors SUNOVION PHARMACEUTICALS INC. (US) 2017-12-05 US disclosed
US-20160139162-A1 Inhibitors Of Fatty Acid Amide Hydrolase And Monoacylglycerol Lipase For Modulation Of Cannabinoid Receptors NORTHEASTERN UNIVERSITY 2016-05-19 US disclosed
US-20160139162-A1 Inhibitors Of Fatty Acid Amide Hydrolase And Monoacylglycerol Lipase For Modulation Of Cannabinoid Receptors NORTHEASTERN UNIVERSITY 2016-05-19 US disclosed
US-20160139162-A1 Inhibitors Of Fatty Acid Amide Hydrolase And Monoacylglycerol Lipase For Modulation Of Cannabinoid Receptors NORTHEASTERN UNIVERSITY 2016-05-19 US disclosed
CN-103038229-B Heteroaryl compounds and methods of use thereof SUNOVION PHARMACEUTICALS INC. (US) 2016-05-11 CN disclosed
US-20110166138-A1 Inhibitors of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase for Modulation of Cannabinoid Receptors NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2011-07-07 US disclosed
WO-2009117444-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE AND MONOACYLGLYCEROL LIPASE FOR MODULATION OF CANNABINOID RECEPTORS NORTHEASTERN UNIVERSITY (US) 2009-09-24 WO disclosed
EP-0365030-B1 Imidazole compound and process for preparing the same ISHIHARA SANGYO KAISHA (JP) 1994-01-26 EP disclosed
EP-0298196-B1 IMIDAZOLE COMPOUNDS AND BIOCIDAL COMPOSITIONS COMPRISING THE SAME ISHIHARA SANGYO KAISHA, LTD. (JP) 1993-06-02 EP disclosed
CN-1016309-B BIOLOGICAL LETHAL AGENT COMPOSITION ISHIHARA SANGYO KAISHA (JP) 1992-04-22 CN disclosed
US-5023336-A Fungicides, biocides ISHIHARA SANGYO KAISHA LTD. (JP) 1991-06-11 US disclosed
US-4995898-A Imidazole compounds and biocidal composition comprising the same for controlling harmful organisms ISHIHARA SANGYO KAISHA, LTD. (JP) 1991-02-26 US disclosed
EP-0365030-A1 Imidazole compound and process for preparing the same ISHIHARA SANGYO KAISHA, Ltd. (JP) 1990-04-25 EP disclosed
EP-0298196-A1 Imidazole compounds and biocidal compositions comprising the same ISHIHARA SANGYO KAISHA, LTD. (JP) 1989-01-11 EP disclosed
CN-88101228-A Imidazolium compounds and the biocides that contains this compound that is used for controlling harmful organism 1988-12-07 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180037590-A1 SUBSTITUTED QUINOLINES AS PDE-10 INHIBITORS PDE10A, PDE2A, PDE3A TSHR 2306/4885FAAH 902/4885LMNA 3470/4885
US-10562916-B2 Substituted quinoxalines as PDE-10 inhibitors PDE4A, PDE2A, PDE9A TSHR 2874/4885FAAH 1145/4885LMNA 3129/4885
US-20110166138-A1 Inhibitors of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase for Modulation of Cannabinoid Receptors FAAH, FAAH2, MGLL TSHR 616/4885FAAH 1/4885LMNA 3178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.